These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

967 related items for PubMed ID: 23244745

  • 21. Measles, mumps, rubella and VZV: importance of serological testing of vaccine-preventable diseases in young adults living with HIV in Germany.
    Schwarze-Zander C, Draenert R, Lehmann C, Stecher M, Boesecke C, Sammet S, Wasmuth JC, Seybold U, Gillor D, Wieland U, Kümmerle T, Strassburg CP, Mankertz A, Eis-Hübinger AM, Jäger G, Fätkenheuer G, Bogner JR, Rockstroh JK, Vehreschild JJ.
    Epidemiol Infect; 2017 Jan; 145(2):236-244. PubMed ID: 27780480
    [Abstract] [Full Text] [Related]

  • 22. Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand.
    Chaiwarith R, Praparattanapan J, Nuket K, Kotarathitithum W, Supparatpinyo K.
    BMC Infect Dis; 2016 Apr 30; 16():190. PubMed ID: 27138005
    [Abstract] [Full Text] [Related]

  • 23. The combination measles, mumps, rubella and varicella vaccine in healthy children.
    Arbeter AM, Baker L, Starr SE, Plotkin SA.
    Dev Biol Stand; 1986 Apr 30; 65():89-93. PubMed ID: 3030864
    [Abstract] [Full Text] [Related]

  • 24. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy.
    Madi N, Altawalah H, Alfouzan W, Al-Nakib W, Al-Roumi E, Jeragh A.
    J Med Virol; 2020 Aug 30; 92(8):963-970. PubMed ID: 31919861
    [Abstract] [Full Text] [Related]

  • 25. Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants.
    D'Angio CT, Boohene PA, Mowrer A, Audet S, Menegus MA, Schmid DS, Beeler JA.
    Pediatrics; 2007 Mar 30; 119(3):e574-9. PubMed ID: 17332177
    [Abstract] [Full Text] [Related]

  • 26. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T, McIntyre P, Roberton D, Descamps D.
    Vaccine; 2002 Dec 13; 21(3-4):281-9. PubMed ID: 12450703
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
    Leung JH, Hirai HW, Tsoi KK.
    Expert Rev Vaccines; 2015 Dec 13; 14(8):1149-57. PubMed ID: 26081133
    [Abstract] [Full Text] [Related]

  • 32. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
    Shinefield HR, Black S, Kuter BJ.
    J Infect Dis; 2008 Mar 01; 197 Suppl 2():S152-5. PubMed ID: 18419390
    [Abstract] [Full Text] [Related]

  • 33. Prevalence of measles, mumps, rubella, and varicella susceptibility among health science students in a University in India.
    Arunkumar G, Vandana KE, Sathiakumar N.
    Am J Ind Med; 2013 Jan 01; 56(1):58-64. PubMed ID: 22467356
    [Abstract] [Full Text] [Related]

  • 34. Low immunity against vaccine preventable diseases in Turkish HIV cohort.
    Candevir A, Kuşcu F, Yıldırım F, Kömür S, Şentürk GÇ, İnal AS, Eser F, Çetiner S, Kurtaran B, Taşova Y.
    Turk J Med Sci; 2021 Oct 21; 51(5):2311-2317. PubMed ID: 33984893
    [Abstract] [Full Text] [Related]

  • 35. Seroprevalence survey of varicella, measles, rubella, and hepatitis A and B viruses in a multinational healthcare workforce in Saudi Arabia.
    Almuneef MA, Memish ZA, Balkhy HH, Otaibi B, Helmi M.
    Infect Control Hosp Epidemiol; 2006 Nov 21; 27(11):1178-83. PubMed ID: 17080374
    [Abstract] [Full Text] [Related]

  • 36. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
    Reisinger KS, Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B, Matson DO, Silas PE, Schödel F, Gress JO, Kuter BJ, Protocol 014 Study Group for ProQuad.
    Pediatrics; 2006 Feb 21; 117(2):265-72. PubMed ID: 16452343
    [Abstract] [Full Text] [Related]

  • 37. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C, Brönnimann R, Tischer A, Stettler P, Durrer P, Gaedicke G.
    Pediatr Infect Dis J; 2005 Dec 21; 24(12):1083-8. PubMed ID: 16371870
    [Abstract] [Full Text] [Related]

  • 38. Kinetics of antibody and memory B cell responses after MMR immunization in children and young adults.
    Kakoulidou M, Ingelman-Sundberg H, Johansson E, Cagigi A, Farouk SE, Nilsson A, Johansen K.
    Vaccine; 2013 Jan 11; 31(4):711-7. PubMed ID: 23174196
    [Abstract] [Full Text] [Related]

  • 39. Prevalence of anti-rubella, anti-measles and anti-mumps IgG antibodies in neonates and pregnant women in Catalonia (Spain) in 2013: susceptibility to measles increased from 2003 to 2013.
    Plans P, de Ory F, Campins M, Álvarez E, Payà T, Guisasola E, Compte C, Vellbé K, Sánchez C, Lozano MJ, Aran I, Bonmatí A, Carreras R, Jané M, Cabero L.
    Eur J Clin Microbiol Infect Dis; 2015 Jun 11; 34(6):1161-71. PubMed ID: 25666082
    [Abstract] [Full Text] [Related]

  • 40. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L, Germann D, Bally F, Schopfer K.
    Eur J Epidemiol; 1997 Jan 11; 13(1):61-6. PubMed ID: 9062781
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 49.